Señales en vivo de MOR.DE | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 11:35):

Stats
Volumen de hoy	46 604.00
Volumen promedio	310 823
Capitalización de mercado	2.52B
EPS	€0 ( 2024-04-29 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-12.10
ATR14	€0.0790 (0.12%)

Volumen Correlación

Largo: 0.17 (neutral)

Corto: 0.21 (neutral)

Signal:(62.473) Neutral

MorphoSys AG Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

MorphoSys AG Correlación - Moneda/Commodity

-0.33
( neutral )

-0.27
( neutral )

0.00
( neutral )

-0.33
( neutral )

-0.50
( weak negative )

0.23
( neutral )

MorphoSys AG Finanzas

Annual	2023
Ingresos:	€238.28M
Beneficio Bruto:	€179.92M (75.51 %)
EPS:	€-5.53

FY	2023
Ingresos:	€238.28M
Beneficio Bruto:	€179.92M (75.51 %)
EPS:	€-5.53

FY	2022
Ingresos:	€278.27M
Beneficio Bruto:	€229.65M (82.53 %)
EPS:	€-4.42

FY	2021
Ingresos:	€179.61M
Beneficio Bruto:	€147.42M (82.08 %)
EPS:	€-15.40

Financial Reports:

No articles found.

MorphoSys AG

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.